Article
Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.
BJU international - 1 Oct 2006
Rini Brian I, Jaeger Erich, Weinberg Vivian, Sein Nancy, Chew Karen, Fong Kristen, Simko Jeffery, Small Eric J, Waldman Frederic M
Abstract excerpt
OBJECTIVE: To describe the relationship among patient characteristics, Von Hippel-Lindau (VHL) gene status and clinical outcome in metastatic renal cell carcinoma (RCC) in patients receiving vascular endothelial growth factor (VEGF)-targeted therapy. PATIENTS AND METHODS: All patients with metastatic RCC who received therapy with interferon-alpha plus bevacizumab, SU11248 or AG013736 at the authors' institution...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.